Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945

Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945

Abstract Fourth-generation EGFR tyrosine kinase are in development to overcome common resistance mutations. We performed deep mutational scanning (DMS) of the EGFR kinase domain in the context of L858R by introducing a saturation library of ~17,000 variants into Ba/F3 cells. DMS library-expressing c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yueyang Wang, Yuan Hao, Michela Ranieri, Tigran M. Abramyan, Lev Tsidilkovski, Michelle Hollenberg, Alfonso Lopez, Xavier T. R. Moore, Fiona Sherman, Jiehui Deng, Hayk Saribekyan, Garegin Papoian, Kwok-Kin Wong, Elaine Shum, John T. Poirier
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-08-01
Series:	npj Precision Oncology
Online Access:	https://doi.org/10.1038/s41698-025-01086-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Design and Generation of MLPA Probe Sets for Combined Copy Number and Small-Mutation Analysis of Human Genes: EGFR as an Example
by: Malgorzata Marcinkowska, et al.
Published: (2010-01-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
by: Jiannong Li, et al.
Published: (2013-11-01)

The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma
by: Ismail Beypinar, et al.
Published: (2019-08-01)

Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
by: Lianxi Song, et al.
Published: (2025-09-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
by: Marianna Peroni, MD, et al.
Published: (2025-08-01)

Detection of EGFR Mutations in Bronchial Wash from Iraqi patients with nonsmall Cell Lung Cancer (NSCLC)
by: Hayfa H. Hassani, et al.
Published: (2014-09-01)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
by: Huijuan Wang, et al.
Published: (2020-01-01)

CT-based radiomics analysis for predicting EGFR and ALK mutational status in non‑small cell lung cancer
by: Ruimin He, et al.
Published: (2025-07-01)

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
by: Wengang Zhang, et al.
Published: (2025-05-01)

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer
by: Yongfeng Yu, et al.
Published: (2025-07-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

The targeting of AKR1C1 synergizes with gefitinib via the STAT3 signaling pathway in EGFR-mutated NSCLC
by: Linlin Chang, et al.
Published: (2025-11-01)

EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features
by: Karin Alvarez, et al.
Published: (2017-09-01)

Case Report: A Bilateral Synchronous Primary Non‐Small Cell Lung Cancer Patient With Two Different EGFR Mutations
by: Thanh‐Dung Quach, et al.
Published: (2025-08-01)

Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features
by: Peng Hao, et al.
Published: (2024-11-01)

Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1-mutated oral squamous cell carcinoma
by: Yumeng Lin, et al.
Published: (2025-08-01)

Accessing utility of immunohistochemistry, PD-L1 correlation with stage of cancer and EGFR mutation with disease survival in primary lung carcinoma
by: Kartavya Kumar Verma, et al.
Published: (2025-06-01)

EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens
by: Mariëlle I. Gallegos Ruiz, et al.
Published: (2007-01-01)

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)

Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC
by: Zhidong Yin, et al.
Published: (2025-08-01)

Non-invasive identification of TKI-resistant NSCLC: a multi-model AI approach for predicting EGFR/TP53 co-mutations
by: Jiayi Li, et al.
Published: (2025-07-01)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
by: E. V. Karabina, et al.
Published: (2018-11-01)

Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma
by: Fouzia Nawab, et al.
Published: (2025-08-01)

T790M-EGFR mutation frequency in advanced NSCLC patients on progression from a previous TKI therapy: results from a Portuguese study
by: Encarnação Teixeira, et al.
Published: (2021-09-01)

A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N
by: Julian Behn, et al.
Published: (2025-01-01)

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
by: Lingbo Bao, et al.
Published: (2025-08-01)

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature
by: Huijuan Zhu, et al.
Published: (2025-01-01)

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations
by: Le LT, et al.
Published: (2025-07-01)

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review
by: Chuang Yang, et al.
Published: (2025-08-01)

Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy
by: Koken Ameku, et al.
Published: (2020-01-01)

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
by: Kibum Kim, et al.
Published: (2025-01-01)

Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I–III Resected NSCLC Without Known EGFR Mutations: The RESECT Study
by: Jhanelle E. Gray, et al.
Published: (2025-05-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
by: Ryan Cooper, et al.
Published: (2024-11-01)